Sagimet Biosciences Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Sagimet Biosciences Inc 's ROA in the second quarter of 2026?
Sagimet Biosciences Inc recorded a cumulative net loss of $-47 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -26.56%.

However, within the Healthcare sector 426 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3736, from total ROA ranking in the first quarter of 2026 at 4434.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	158.79 %	-26.28 %	-27.73 %	-32.75 %	-27.63 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-47	-44	-51	-58	-59
Return On Assets (TTM)	-26.56 %	-35.45 %	-38.57 %	-40.19 %	-37.29 %
SGMT's Total Ranking	# 3736	# 4434	# 3908	# 3920	# 3923
Total Assets (TTM) in million	356	108	116	129	137
Seq. Total Assets Change	230.01 %	-7.49 %	-9.9 %	-5.91 %	-6 %
Seq. Net Income Change	-	-	-	-	-

SGMT's 5 Years Annual ROA >> Back to SGMT Management Effectiveness >> Compare SGMT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 166
Sector	# 427
Overall	# 3615

Return On Assets Statistics
High	Average	Low
-20.06 %	-32.42 %	-43.87 %
(Jun 30 2024)		(Dec 31 2023)

Financial Statements
Sagimet Biosciences Inc 's Assets	$ 356 million	SGMT's Balance sheet
Sagimet Biosciences Inc 's Income	$ -14 million	Quarterly SGMT's Income Statement
SGMT's Income by Division		See SGMT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	FY	FY
Y / Y Total Assets Change	-27.73 %	66.65 %	-	-	-
Total Assets in million	116	161	97	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-51	-46	-28	0	0
Annual Return On Assets	-43.82 %	-28.27 %	-28.82 %	-	-

SGMT's 5 Years Annual ROA >> Back to SGMT Management Effectiveness >> Compare SGMT ROA to its Competitors

More Return On Assets Ratios
SGMT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SGMT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SGMT's Competitors
Subscribers only: Roa for Sagimet Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for SGMT's Customers

You may also want to know
SGMT's Roi	SGMT's Inventory Turnover Ratio	SGMT's Growth Rates	SGMT's Dividend Comparisons
	SGMT's Profitability Ratios	SGMT's Asset Turnover Ratio	SGMT's Dividend Growth
SGMT's Roe	SGMT's Valuation Ratios	SGMT's Financial Strength Ratios	SGMT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T04:00:56+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.